Clinicopathological risk factors for recurrence after neoadjuvant chemotherapy and radical hysterectomy in cervical cancer

World Journal of Surgical Oncology

Yongxia Yang¹  Yunhai Yu¹  Hui Xu¹  Weihua Lu²  Lin Zhu¹  Huali Wang¹ 

[1] Gynecology Department, The Second Hospital of Shandong University, No. 247 Beiyuan Street, Jinan, Shandong 250033, China;Paediatrics Department, The First Hospital of Ningyang County, Taian, Shandong 271400, China

关键词: Risk factors;    Recurrence;    Radical hysterectomy;    Cervical cancer;   

Others  :  820801
DOI  :  10.1186/1477-7819-11-301

 received in 2013-05-23, accepted in 2013-10-25,  发布年份 2013

【 摘 要 】

Background

Cervical cancer is one of the common gynecological malignancies with a high recurrence rate after surgery. This study aimed to analyze the clinicopathological risk factors for recurrence after the surgical treatment of cervical cancer and provide the basis for the prevention of recurrence and an improvement of prognosis.

Methods

A total of 424 cervical cancer cases between 1 January 1998 and 31 December 2011 undergoing surgical treatment were studied retrospectively, of which 23 cases had recurrences. Relevant recurrence risk factors were evaluated by univariate and multivariate analyses between recurrence group and non-recurrence group.

Results

Using univariate analysis, tumor differentiation, clinical stage, pelvic lymph node metastasis, postoperative radiotherapy and postoperative chemotherapy were related to recurrence of cervical cancer. Multivariate COX model analysis revealed that pelvic lymph node metastasis and postoperative chemotherapy had an impact on recurrence rate. Moderately and highly differentiated tumor, advanced clinical stage, and positive pelvic lymph nodes indicated a high recurrence rate of cervical cancer. Postoperative chemotherapy and radiotherapy can effectively reduce the recurrence rate.

Conclusions

In conclusion, cervical lymph node metastasis and postoperative chemotherapy are two independent factors for recurrence of cervical cancer after radical surgery.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Waggoner SE: Cervical cancer. Lancet 2003, 361:2217-2225.
• [2]Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009, 105:103-104.
• [3]Gray HJ: Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy. J Natl Compr Canc Netw 2008, 6:47-52.
• [4]Hirakawa M, Nagai Y, Toita T, Kudaka W, Inamine M, Ogawa K, Murayama S, Aoki Y: High-risk group for locoregional recurrence in patients with stage IB-IIB squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Anticancer Res 2011, 31:1437-1441.
• [5]Lissoni A, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M: A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol 2009, 20:660-665.
• [6]Gadducci A, Teti G, Barsotti C, Tana R, Fanucchi A, Orlandini C, Fabrini MG, Genazzani AR: Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy. Anticancer Res 2010, 30:201-208.
• [7]Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermudez A, Snaidas L, Vighi S, Gomez RN, di Paola G: Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 1997, 67:61.
• [8]Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE: Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003, 21:690-696.
• [9]Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
• [10]Inoue T, Morita K: The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer 1990, 65:1923-1927.
• [11]Liu MT, Hsu JC, Liu WS, Wang AY, Huang WT, Chang TH, Pi CP, Huang CY, Huang CC, Chou PH: Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post‒operative adjuvant therapy. Eur J Cancer Care 2008, 17:174-181.
• [12]Girardi F, Lichtenegger W, Tamussino K, Haas J: The importance of parametrial lymph nodes in the treatment of cervical cancer. Gynecol Oncol 1989, 34:206-211.
• [13]Smiley LM, Burke TW, Silva EG, Morris M, Gershenson DM, Wharton JT: Prognostic factors in stage IB squamous cervical cancer patients with low risk for recurrence. Obstet Gynecol 1991, 77:271-275.
• [14]Singh N, Arif S: Histopathologic parameters of prognosis in cervical cancer - a review. Int J Gynecol Cancer 2004, 14:741-750.
• [15]Chen H, Liang C, Zhang L, Huang S, Wu X: Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study. Gynecol Oncol 2008, 110:308.
• [16]Rydzewska L, Tierney J, Vale CL, Symonds PR: Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2010., 1CD007406
• [17]Kukura V, Ciglar S, Markulin-Grgić L, Šantek F: Adjuvant therapy after radical surgery of cervical cancer: Zagreb experience. Collegium Antropol 2007, 31:155-158.
• [18]Yamakawa Y, Fujimura M, Hidaka T, Hori S, Saito S: Neoadjuvant intraarterial infusion chemotherapy in patients with stage IB2–IIIB cervical cancer. Gynecol Oncol 2000, 77:264-270.
• [19]Liu MT, Hsu JC, Liu WS, Wang AY, Huang WT, Chang TH, Pi CP, Huang CY, Huang CC, Chou PH: Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post‒operative adjuvant therapy. Eur J Cancer Care 2007, 17:174-181.
• [20]Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ: A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006, 65:169-176.